Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP-LATimus)

被引:6
作者
Martin, Claudio [1 ]
Enrico, Diego [2 ]
Mas, Luis [3 ]
Patane, Ana Karina [4 ]
Arrieta, Oscar [5 ]
Soria, Tannia [6 ]
Cardona, Andres F. [7 ,8 ,9 ]
Ruiz-Patino, Alejandro [8 ,9 ]
Ruiz, Rossana [3 ]
Rioja, Patricia [3 ]
Lozano, Sophia [3 ]
Zatarain-Barron, Zyanya Lucia [5 ]
Barron, Feliciano [5 ]
Puparelli, Carmen [1 ]
Tsou, Florencia [1 ]
Corassa, Marcelo P. [10 ]
Freitas, Helano C. [10 ]
Cordeiro de Lima, Vladmir Claudio [10 ]
Rojas, Leonardo [7 ,9 ,11 ]
Ordonez-Reyes, Camila [8 ]
Corrales, Luis [12 ]
Sotelo, Carolina [8 ]
Rodriguez, July [8 ]
Ricaurte, Luisa [8 ]
avila, Jenny [8 ]
Archila, Pilar [8 ]
Rosell, Rafael [13 ]
Cuello, Mauricio [14 ]
Remon, Jordi [15 ]
机构
[1] Alexander Fleming Canc Inst, Thorac Oncol Unit, Buenos Aires, DF, Argentina
[2] Alexander Fleming Canc Inst, Clin Oncol Dept, Buenos Aires, DF, Argentina
[3] Inst Nacl Enfermedades Neoplas INEN, Oncol Dept, Thorac Oncol Unit, Lima, Peru
[4] Hosp Rehabil Maria Ferrer, Buenos Aires, DF, Argentina
[5] Inst Nacl Cancerol INCan, Thorac Oncol Unit, Mexico City, DF, Mexico
[6] Hosp SOLCA, Thorac Oncol Unit, Quito, Ecuador
[7] Clin Country, Clin & Traslat Oncol Grp, Bogota, Colombia
[8] Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia
[9] Univ Bosque, Mol Oncol & Biol Syst Res Grp Fox G, Bogota, Colombia
[10] AC Camargo Canc Ctr, Dept Med Oncol, Sao Paulo, Brazil
[11] Clin Colsanitas, Oncol Dept, Bogota, Colombia
[12] Hosp San Juan Dios, Ctr Invest & Manejo Canc CIMCA, Thorac Oncol Unit, San Jose, Costa Rica
[13] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Canc Biol & Precis Med Program, Barcelona, Spain
[14] Univ Republ UdeLAR, Hosp Clin, Med Oncol Dept, Montevideo, Uruguay
[15] Hosp HM Delfos, HM Hosp, Ctr Integral Oncol Clara Campal HM CIOCC, Dept Med Oncol, Barcelona, Spain
关键词
cohort studies; Latin America; medical oncology; thymoma;
D O I
10.1111/1759-7714.13901
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Thymomas are a group of rare neoplasms of the anterior mediastinum. The objective of this study was to describe the demographics, clinical characteristics and treatment approaches in Latin America. Methods This was a retrospective multicenter cohort study including patients with histologically proven thymomas diagnosed between 1997 and 2018. Demographics, clinicopathological characteristics and therapeutic outcomes were collected locally and analyzed in a centralized manner. Results A total of 135 patients were included. Median age at diagnosis was 53 years old (19-84), 53.3% (n = 72) of patients were female and 87.4% had an ECOG performance score ranging from 0-1. A total of 47 patients (34.8%) had metastatic disease at diagnosis. Concurrent myasthenia gravis occurred in 21.5% of patients. Surgery was performed in 74 patients (54.8%), comprising 27 (20%) tumorectomies and 47 (34.8%) thymectomies. According to the Masaoka-Koga system, overall survival (OS) at five-years was 73.4%, 63.8% and 51%, at stages I-II, III-IVA and IVB, respectively (p = 0.005). Furthermore, patients with low lactate dehydrogenase (LDH) (<= 373 IU/L) at baseline and myasthenia gravis concurrence showed significantly better OS (p = 0.001 and p = 0.008, respectively). In multivariate analysis, high LDH levels (HR 2.8 [95% confidence interval [CI]: 1.1-7.8]; p = 0.036) at baseline and not performing a surgical resection (HR 4.1 [95% CI: 1.3-12.7]; p = 0.016) were significantly associated with increased risk of death. Conclusions Our data provides the largest insight into the clinical characteristics and outcomes of patients with thymomas in Latin America. Survival in patients with thymomas continues to be very favorable, especially when subjected to adequate local control.
引用
收藏
页码:1328 / 1335
页数:8
相关论文
共 41 条
  • [11] Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
    Girard, N.
    Ruffini, E.
    Marx, A.
    Faivre-Finn, C.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : V40 - V55
  • [12] Hallmarks of Cancer: The Next Generation
    Hanahan, Douglas
    Weinberg, Robert A.
    [J]. CELL, 2011, 144 (05) : 646 - 674
  • [13] Standard Outcome Measures for Thymic Malignancies
    Huang, James
    Detterbeck, Frank C.
    Wang, Zuoheng
    Loehrer, Patrick J., Sr.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : 2017 - 2023
  • [14] Kelly Ronan J, 2014, Am Soc Clin Oncol Educ Book, pe367, DOI 10.14694/EdBook_AM.2014.34.e367
  • [15] Therapy for thymic epithelial tumors: A clinical study of 1,320 patients from Japan
    Kondo, K
    Monden, Y
    [J]. ANNALS OF THORACIC SURGERY, 2003, 76 (03) : 878 - 884
  • [16] State-of-the-art classification and multimodality treatment of malignant thymoma
    Koppitz, Hannah
    Rockstroh, Juergen K.
    Schueller, Heinrich
    Standop, Jens
    Skowasch, Dirk
    Mueller-Hermelink, Hans Konrad
    Schmidt-Wolf, Ingo G. H.
    [J]. CANCER TREATMENT REVIEWS, 2012, 38 (05) : 540 - 548
  • [17] Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma
    Lemma, Girum L.
    Lee, Ju-Whei
    Aisner, Seena C.
    Langer, Corey J.
    Tester, William J.
    Johnson, David H.
    Loehrer, Patrick J., Sr.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : 2060 - 2065
  • [18] LEWIS JE, 1987, CANCER-AM CANCER SOC, V60, P2727, DOI 10.1002/1097-0142(19871201)60:11<2727::AID-CNCR2820601125>3.0.CO
  • [19] 2-D
  • [20] Elevated pretreatment serum lactate dehydrogenase level predicts inferior overall survival and disease-free survival after resection of thymic carcinoma
    Liu, Qianwen
    Fu, Xiayu
    Su, Xiaodong
    Wang, Xin
    Zhang, Yijun
    Yang, Hong
    Hu, Yi
    Wen, Jing
    Fu, Jianhua
    [J]. JOURNAL OF THORACIC DISEASE, 2017, 9 (11) : 4550 - 4560